FDA, CDC Urge Pause in J&J COVID-19 Vaccination, Citing “Rare” Blood Clots

The FDA and U.S. Centers for Disease Control and Prevention (CDC) are recommending that U.S. states pause their administration of Johnson & Johnson’s Janssen COVID-19 Vaccine Candidate while they review six reported cases of patients developing what they termed rare and severe blood clots after receiving the vaccine.

Read the full article here

Related Articles